

References

- Adibkia K, Javadzadeh Y, Dastmalchi S, Mohammadi G, Niri FK, Alaei-Beirami M. Naproxen-eudragit RS100 nanoparticles: preparation and physicochemical characterization. *Colloids Surf B Biointerfaces*. 2011;83:155-9.
- Agrawal AG, Kumar A, Gide PS. Formulation of solid self-nanoemulsifying drug delivery systems using N-methyl pyrrolidone as cosolvent. *Drug Dev Ind Pharm*. 2015;41:594-604.
- Ahmed TA, Alharby YA, El-Helw AR, Hosny KM, El-Say KM. Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation. *Drug Des Devel Ther*. 2016;10:405-15.
- Ali KA, Mukherjee B, Bandyopadhyay AK. Formulation development and in vitro evaluation of solidified self-microemulsion in the form of tablet containing atorvastatin calcium. *Drug Dev Ind Pharm*. 2013;39:1742-9.
- Allemann E, Gurny R, Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size. *Int J Pharm*. 1992;87:247-53.
- Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics, 2008 ed. European Heart Network, 2008.
- Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharm Res*. 1995;12:413-20.
- Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates—a review. *J Control Release*. 2008;128:185-99.
- Aprahamian M, Michel C, Humbert W, Devissaguet JP, Damge C. Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. *Biol. Cell*. 1987;61:69-76
- Arias JL, Gallardo V, Gomez-Lopera SA, Plaza RC, Delgado AV. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. *J Control Release*. 2001;77:309-21.
- Badimón JJ, Santos-Gallego CG, Badimón L. Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going? *Rev. Esp. Cardiol*. 2010;63:20-35.
- Badimon L, Vilahur G. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. *Ann. N.Y. Acad. Sci*. 2012;1254:18-32.
- Bahrami G, Mohammadi B, Mirzaeei S, Kiani A. Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography

- with UV detection. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2005;826:41-5.
- Bardajee GR, Vancaeyzeele C, Haley JC, Li AY, Winnik MA. Synthesis, characterization and energy transfer studies of dye-labeled poly(butyl methacrylate) latex particles prepared by miniemulsion polymerization. *Polymer.* 2007;48:5839-49.
- Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, Moran AE. Global overview of the epidemiology of atherosclerotic cardiovascular disease. *Arch Med Res.* 2015;46:328-38.
- Baruch-Sharon S, Margel S. Synthesis and characterization of polychloromethylstyrene nanoparticles of narrow size distribution by emulsion and miniemulsion polymerization processes. *Colloid Polym Sci.* 2010;288:869-77.
- Beig A, Miller JM, Dahan A. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption. *Eur J Pharm Biopharm.* 2012;81:386-91.
- Bilati U, Allemann E, Doelker E. Sonication parameters for the preparation of biodegradable nanocapsules of controlled size by the double emulsion method. *Pharm Dev Technol.* 2003;8:1-9.
- Biswal PK, Pani NR, Dixit PK. Effects of carbohydrate polymers in self-microemulsified tablets on the bioavailability of atorvastatin: In vitro–in vivo study. *Life Sci.* 2015;135:92-100.
- Black CDV, Gregoriadis G. Intracellular fate and effect of liposome-entrapped Actinomycin-D Injected into Rats. *Biochem Soc T.* 1974;2:869-71.
- Braunecker WA, Matyjaszewski K. Controlled/living radical polymerization: features, developments, and perspectives. *Prog Polym Sci.* 2007;32:93-146.
- Bressolle F, Bromet-Petit M, Audran M, Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics. *J Chromatogr B Biomed Appl.* 1996;686:3-10.
- de Carvalho SM, Noronha CM, Floriani CL, Lino RC, Rocha G, Bellettini IC, et al. Optimization of α -tocopherol loaded solid lipid nanoparticles by central composite design. *Ind Crops and Prod.* 2013;49:278-85.
- Chakraborty S, Shukla D, Jain A, Mishra B, Singh S. Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. *J Colloid Interface Sci.* 2009;335:242-9.
- Chang J, Jallouli Y, Kroubi M, Xu-bo Y, Feng W, Chun-sheng K, Pei-yu P, Betbeder D. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier. *Int J Pharm* 2009;379:285-92.
- Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. *Pharmacol Ther.* 2006;111:893-908.

- Chaubey P, Patel RR, Mishra B. Development and optimization of curcumin-loaded mannosylated chitosan nanoparticles using response surface methodology in the treatment of visceral leishmaniasis. *Expert Opin Drug Deliv.* 2014;11:19-21.
- Chaurasia S, Patel RR, Chaubey P, Kumar N, Khan G, Mishra B. Lipopolysaccharide based oral nanocarriers for the improvement of bioavailability and anticancer efficacy of curcumin. *Carbohydr Polym.* 2015;130:9-17.
- Chawla R, Jaiswal S, Mishra B. Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design. *Expert Opin Drug Deliv.* 2014;11:31-43.
- Choi BG, Vilahur G, Viles-Gonzalez JF, Badimon JJ. The role of high-density lipoprotein cholesterol in atherothrombosis. *Mt Sinai J Med.* 2006;73: 690-701.
- Choi SW, Kim JH. Design of surface-modified poly(dl-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. *J Control Release.* 2007;122:24-30.
- Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. *J Control Release.* 2002;83:389-400.
- Choudhary A, Rana AC, Aggarwal G, Kumar V, Zakir F. Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. *Acta Pharm Sin B.* 2012;2:421-8.
- Cicha I, Singh R, Garlichs CD, Alexiou C. Nano-biomaterials for cardiovascular applications: Clinical perspective. *J Control Release.* 2016;229:23-36.
- Costa C, Santos AF, Fortuny M, Araujo PHH, Sayer C. Kinetic advantages of using microwaves in the emulsion polymerization of MMA. *Mater Sci Eng C.* 2009;29:415-9.
- Costa P, Sousa Lobo JM. Modelling and comparison of dissolution profiles. *Eur J Pharm Sci.* 2001;13:123-33.
- Crespy D, Landfester K. Synthesis of polyvinylpyrrolidone/silver nanoparticles hybrid latex in non-aqueous miniemulsion at high temperature. *Polymer.* 2009;50:1616-20.
- Crespy D, Stark M, Hoffmann-Richter C, Ziener U, Landfester K. Polymeric nanoreactors for hydrophilic reagents synthesized by interfacial polycondensation on miniemulsion droplets. *Macro-molecules.* 2007;40:3122-35.
- Cunningham MF. Controlled/living radical polymerization in aqueous dispersed systems. *Prog Polym Sci.* 2008;33:365-98.

- Czajkowska-Kośnik A, Szekalska M, Amelian A, Szymańska E, Winnicka K. Development and evaluation of liquid and solid self-emulsifying drug delivery systems for atorvastatin. *Molecules*. 2015;20:21010-22.
- Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. *J Clin Lipidol*. 2013;7:102-8.
- Daglar B, Ozgur E, Corman ME, Uzun L, Demirel GB. Polymeric nanocarriers for expected nanomedicine: current challenges and future prospects. *RSC Adv*. 2014;4:48639-59.
- Danhier F, Ansorena E, Silva JM, Coco R, Breton AL, Pr at V. PLGA-based nanoparticles: an overview of biomedical applications. *J Control Release*. 2012;161:505-22.
- Danicher L, Frere Y, Calve AL. Synthesis by interfacial polycondensation of polyamide capsules with various sizes. Characteristics and properties. *Macromol Symp*. 2000;151:387-92.
- Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat Rev Drug Discov*. 2008; 7: 771-82.
- De Jaeghere F, Allemann E, Leroux JC, Stevels W, Feijen J, Doelker E, Gurny R. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. *Pharm Res*. 1999;16:859-66.
- Deepak V, Pandian SBRK, Kalishwaralal K, Gurunathan S. Purification, immobilization, and characterization of nattokinase on PHB nanoparticles. *Bioresour Technol*. 2009;100:6644-6.
- des Rieux A, Fievez V, Garinot M, Schneider YJ, Pr at V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. *J Control Release*. 2006;116:1-27.
- Dong H, Gao Y, Sinko PJ, Wu Z, Xu J, Jia L. The nanotechnology race between China and the United States. *Nanotoday*. 2016;11:7-12.
- Dubuis C, May L, Alonso F, Luca L, Mylonaki I, Meda P, Delie F, Jordan O, D eglise S, Corpataux JM, Saucy F, Haefliger JA. Atorvastatin-loaded hydrogel affects the smooth muscle cells of human veins. *J Pharmacol Exp Ther*. 2013;347:574-81.
- Elshafeey AH, Kamel AO, Awad GA. Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. *Colloids Surf B Biointerfaces*. 2010;75:398-404.
- Ema M, Hara H, Matsumoto M, Hirata-Koizumi M, Hirose A, Kamata E. Evaluation of developmental neurotoxicity of polysorbate 80 in rats. *Reprod Toxicol*. 2008;25:89-99.

- Emerich DF, Thanos CG. Nanotechnology and medicine. *Expert Opin Biol Ther.* 2003;3:655-63.
- Eroglu H, Nemutlu E, Turkoglu OF, Nacar O, Bodur E, Sargon MF, Beskonakli E, Oner L. A Quadruped study on chitosan microspheres containing atorvastatin calcium: preparation, characterization, quantification and in-vivo application. *Chem Pharm Bull.* 2010;58:1161-67.
- Ethirajan A, Ziener U, Landfester K. Surface-functionalized polymeric nanoparticles as templates for biomimetic mineralization of hydroxyapatite. *Chem Mater.* 2009;21:2218-25.
- Fan YF, Wang YN, Fan YG, Ma JB. Preparation of insulin nanoparticles and their encapsulation with biodegradable polyelectrolytes via the layer-by-layer adsorption. *Int J Pharm.* 2006;324:158-67.
- Fan Z, Wu J, Fang X, Sha X. A new function of Vitamin E-TPGS in the intestinal lymphatic transport of lipophilic drugs: enhancing the secretion of chylomicrons. *Int J Pharm.* 2013;445:141-7.
- Ferranti V, Marchais H, Chabenat C, Orecchioni AM, Lafont O. Primidone-loaded poly- ϵ -caprolactone nanocapsules: incorporation efficiency and in vitro release profiles. *Int J Pharm.* 1999;193:107-11.
- Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. *Int J Pharm.* 1989;55:R1-R4.
- Francis GA, Annicotte JS, Auwerx J. PPAR agonists in the treatment of atherosclerosis. *Curr Opin Pharmacol.* 2003;3:186-91.
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972;18:499-502.
- Funatsu T, Suzuki K, Goto M, Arai Y, Kakuta H, Tanaka H, Yasuda S, Ida M, Nishijima S, Miyata K. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. *Atherosclerosis.* 2011;157:107-15.
- Galindo-Rodriguez S, Allémann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. *Pharm Res.* 2004;21:1428-39.
- Galindo-Rodriguez SA, Puel F, Briancon S, Allemann E, Doelker E, Fessi H. Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. *Eur J Pharm Sci.* 2005;25:357-67.
- Ganachaud F, Katz JL. Nanoparticles and nanocapsules created using the ouzo effect: spontaneous emulsification as an alternative to ultrasonic and high-shear devices. *Chemphyschem.* 2005;6:209-16.

- Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. *Curr Probl Cardiol.* 2010;35:72-115.
- Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. *Eur J Intern Med.* 2007;18:90-100.
- Glass CK, Witztum JL. Atherosclerosis. the road ahead. *Cell.* 2001;104:503-16.
- Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. *N Engl J Med.* 1989;321:1311-6.
- Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. *Inflamm Res.* 2002;51:58-62.
- Guo Y, Luo J, Tan S, Otieno BO, Zhang Z. The applications of Vitamin E TPGS in drug delivery. *Eur J Pharm Sci.* 2013;49:175-86.
- Ha ES, Baek IH, Cho W, Hwang SJ, Kim MS. Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique. *Chem Pharm Bull.* 2014;62:545-51.
- Han J, Zern BJ, Shuvaev VV, Davies PF, Muro S, Muzykantov V. Acute and chronic shear stress differently regulate endothelial internalization of nanocarriers targeted to platelet-endothelial cell adhesion molecule-1. *ACS Nano.* 2012;6:8824-36.
- Hashem FM, Al-Sawahli MM, Nasr M, Ahmed OA. Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems – enhancement of oral bioavailability. *Drug Des Devel Ther.* 2015;9:3141-52.
- Hashem FM, Al-Sawahli MM, Nasr M, Ahmed OA. Optimized zein nanospheres for improved oral bioavailability of atorvastatin. *Int J Nanomedicine.* 2015;10:4059-69.
- He W, Horn SW, Hussain MD. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. *Int J Pharm.* 2007;334:173-8.
- He X, Ma J, Mercado AE, Xu W, Jabbari E. Cytotoxicity of paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles. *Pharm Res.* 2008;25:1552-62.
- Heinze T, Michealis N, Hornig S. Reactive polymeric nanoparticles based on unconventional dextran derivative. *Eur Polym J.* 2007;43:697-703.
- Holbrook A, Wright M, Sung M, Ribic C, Baker S. Statin-associated rhabdomyolysis: is there a dose-response relationship? *Can J Cardiol.* 2011;27:146-51.
- Hopkins PN. Molecular biology of atherosclerosis. *Physiol Rev.* 2013;93:1317-542.
- Hornig S, Bunjes H, Heinze T. Preparation and characterization of nanoparticles based on dextran–drug conjugates. *J Colloid Interface Sci.* 2009;338:56-62.

- Hornig S, Heinze T. Nanoscale structures of dextran esters. *Carbohydr Polym.* 2007;68:280-6.
- Hou Y, Shao W, Xiao R, Xu K, Ma Z, Johnstone BH, Du Y. Puerh tea aqueous extracts lower atherosclerotic risk factors in a rat hyperlipidemia model. *Exp Gerontol.* 2009;44:434-9.
- Hubbell JA, Chilkoti A. Chemistry. Nanomaterials for drug delivery. *Science.* 2012;337:303-5.
- ICH Q2B, ICH Harmonised Tripartite Guideline "Validation of Analytical Procedures: Methodology", 1996.
- Ishak RA, Osman R. Lecithin/TPGS-based spray-dried self microemulsifying drug delivery systems: In vitro pulmonary deposition and cytotoxicity. *Int J Pharm.* 2015;485:249-60.
- Islam M, Sharma S, Kumar B, Teknos TN. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. *Oral Oncol.* 2013;49:778-86.
- Hao J, Wang F, Wang X, Zhang D, Bi Y, Gao Y, Zhao X, Zhang Q. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. *Eur J Pharm. Sci.* 2012;47:497-505.
- Jahangiri A, Barzegar-Jalali M, Garjani A, Javadzadeh Y, Hamishehkar H, Asadpour-Zeynali K, Adibkia K. Evaluation of physicochemical properties and in vivo efficiency of atorvastatin calcium/ezetimibe solid dispersions. *Eur J Pharm Sci.* 2016;82:21-30.
- Jain A, Ran Y, Yalkowsky SH. Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an Anti-HIV agent): A technical note. *AAPS PharmaSciTech.* 2004;5:65-67.
- Jain AK, Swarnakar NK, Godugu C, Singh RP, Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. *Biomaterials.* 2011;32:503-15.
- Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. *J Pharm Pharmacol.* 1989;41:809-12.
- Jeon HJ, Jeong YI, Jang MK, Park YH, Nah JW. Effect of solvent on the preparation of surfactant-free poly(dl-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics. *Int J Pharm.* 2000;207:99-108.
- Jeong YI, Cho CS, Kim SH, Ko KS, Kim SI, Shim YH, Nah JW. Preparation of poly(dl-lactide-co-glycolide) nanoparticles without surfactant. *J Appl Polym Sci.* 2001;80:2228-36.
- Jiang X, Dausend J, Hafner M, Musyanovych A, Rocker C, Landfester K, Mailander V, Nienhaus GU. Specific effects of surface amines on polystyrene nanoparticles in their interactions with mesenchymal stem cells. *Biomacromolecules.* 2010;11:748-53.

- Julienne VMC, Benoit JP. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. *Pharm Acta Helv.* 1996;71:121-8.
- Juneja R, Roy I. Surface modified PMMA nanoparticles with tunable drug release and cellular uptake. *RSC Adv.* 2014;4:44472-79.
- Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey. *J Supercrit Fluids.* 2001;20:179-219.
- Jung SW, Jeong YI, Kim YH, Kim SH. Self-assembled polymeric nanoparticles of poly(ethylene glycol) grafted pullulan acetate as a novel drug carrier. *Arch Pharm Res.* 2004;27:562-9.
- Karode SK, Kulkarni SS, Suresh AK, Mashelkar RA. New insights into kinetics and thermodynamics of interfacial polymerization. *Chem Eng Sci.* 1998;53:2649-63.
- Khan FN, Dehghan MH. Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation. *AAPS PharmSciTech.* 2011;12:1077-86.
- Khan S, Baboota S, Ali J, Narang RS, Narang JK. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation. *Drug Dev Ind Pharm.* 2016;42:209-20.
- Khoury-Fallouh AN, Roblot-Treupel L, Fessi H, Devissaguet JP, Puisieux F. Development of a new process for the manufacture of poly isobutylcyanoacrylate nanocapsules. *Int J Pharm.* 1986;28:125-36.
- Kim E, Yang J, Choi J, Jin-Suck S, Yong-Min H, Haam S. Synthesis of gold nanorod-embedded polymeric nanoparticles by a nanoprecipitation method for use as photothermal agents. *Nanotechnology.* 2009;20:365602.
- Kim JS, Kim MS, Park HJ, Jin SJ, Lee S, Hwang SJ. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. *Int J Pharm.* 2008;359:211-9.
- Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. *Eur J Pharm Biopharm.* 2008;69:454-65.
- Kim MS, Kim JS, Cho W, Park HJ, Hwang SJ. Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers. *Int J Biol Macromol.* 2013;59:138-42.
- Kim MS, Song HS, Park HJ, Hwang SJ. Effect of solvent type on the nanoparticle formation of atorvastatin calcium by the supercritical antisolvent process. *Chem Pharm Bull.* 2012;60:543-7.
- Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, Ghosh K, Jurek S, Bencherif SA, Bhatta D, Coskun AU, Feldman CL, Wagner DD, Ingber DE. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. *Science.* 2012;337:738-42.

- Kostog M, Kohler S, Liebert T, Heinze T. Pure cellulose nanoparticles from trimethylsilyl cellulose. *Macromol Symp.* 2010;294:96-106.
- Kou L, Sun J, Zhai Y, He Z. The endocytosis and intracellular fate of nanomedicines: Implication for rational design. *Asian j pharm sci.* 2013;8:1-10.
- Kowalczyk A, Trzcinska R, Trzebicka B, Müller AHE, Dworak A, Tsvetanov CB. Loading of polymer nanocarriers: Factors, mechanisms and applications. *Prog. Polym. Sci.* 2014;39:43-86.
- Kreuter J. On the mechanism of termination in heterogeneous polymerization. *J Polym Sci Polym Lett Ed.* 1982;20:543-5.
- Kumar N, Chaurasia S, Patel RR, Khan G, Kumar V, Mishra B. Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile. *Pharm Develop Tech.* 2015:1-12.
- Kumar N, Chaurasia S, Patel RR, Khan G, Kumar V, Mishra B. Atorvastatin calcium loaded PCL nanoparticles: development, optimization, in vitro and in vivo assessments. *RSC Advances.* 2016;6:16520.
- Kumar N, Chaurasia S, Patel RR, Khan G, Kumar V, Mishra B. Development and optimization of atorvastatin calcium loaded oral biodegradable polymeric nanoparticles using central composite design. *Adv Sci Lett.* 2014;20:984-93.
- Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids Surf. B Biointerfaces.* 2010;75:1-18.
- Labiós M, Martínez M, Gabriel F, Guiral V, Martínez E, Aznar J. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. *Thromb Res.* 2005;115:263-70.
- Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. *Acc Chem Res.* 2011;44:1029-38.
- Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. *Br J Cancer.* 2008;99:392-97.
- Lamprecht A, Koenig P, Ubrich N, Maincent P, Neumann D. Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells. *Nanotechnol.* 2006;17:3673-80.
- Lee SC, Oh JT, Jang MH, Chung SI. Quantitative analysis of polyvinyl alcohol on the surface of poly (D, L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. *J Control Release.* 1999;59:123-32.
- Legrand P, Lesieur S, Bochot A, Gref R, Raatjes W, Barratt G, Vau-thier C. Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. *Int J Pharm.* 2007;344:33-43.
- Lennernäs H. Clinical pharmacokinetics of atorvastatin. *Clin Pharmacokinet.* 2003;42:1141-60.
- Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. *Nature.* 2011;473:317-25.

- Limayem I, Charcosset C, Sfar S, Fessi H. Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. *Int J Pharm.* 2006;325:124-31.
- Lince F, Marchisio DL, Barresi AA. Strategies to control the particle size distribution of poly- ϵ -caprolactone nanoparticles for pharmaceutical applications. *J Colloid Interface Sci.* 2008;322: 505-15.
- Liu M, Zhou Z, Wang X, Xu J, Yang K, Cui Q, Chen X, Cao M, Weng J, Zhang Q. Formation of poly(L, D-lactide) spheres with controlled size by direct dialysis. *Polymer.* 2007;48:5767-79.
- Logothetidis S. Nanotechnology: Principles and Applications. In: Logothetidis S. editor. *Nanostructured Materials and Their Applications.* Springer-Verlag Berlin Heidelberg;2012:1-22.
- Lopedota A, Trapani A, Cutrignelli A, Chiarantini L, Pantucci E, Curci R, Manuali E, Trapani G. The use of Eudragit RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. *Eur J Pharm Biopharm.* 2009;72:509-20.
- Lusis AJ. Atherosclerosis. *Nature.* 2000;407:233-41.
- Macias ER, Rodriguez-Guadarrama LA, Cisneros BA, Castaneda A, Mendizabal E, Puig JE. Microemulsion polymerization of methyl methacrylate with the functional monomer N-methylolacrylamide. *Colloid Surf A.* 1995;103:119-26.
- Magee CN, Medani SA, Leavey SF, Conlon PJ, Clarkson MR. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. *Am J Kidney Dis.* 2010;56:e11-5.
- Matyjaszewski K, Xia J. Atom transfer radical polymerization. *Chem Rev.* 2001;101:2921-90.
- Maurya D, Belgamwar V, Tekade A. Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium. *J Pharm Pharmacol.* 2010;62:1599-606.
- McClements DJ, Gumus CE. Natural emulsifiers - Biosurfactants, phospholipids, biopolymers, and colloidal particles: Molecular and physicochemical basis of functional performance. *Adv Colloid Interface Sci.* 2016. (doi: 10.1016/j.cis.2016.03.002)
- Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. *J Control Release.* 2007;119:77-85.
- Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. *Arterioscler Thromb Vasc Biol.* 1998;18:783-93.

- Moinard-Chécot D, Chevalier Y, Briancon S, Beney L, Fessi H. Mechanism of nanocapsules formation by the emulsion-diffusion process. *J Colloid Interface Sci.* 2008;317:458-68.
- Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. Dissolution kinetics of carboxylic acids II: effect of buffers. *J Pharm Sci.* 1981;70:22-32.
- Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. *Nat Rev Immunol.* 2013;13:709-21.
- Mora-Huertas CE, Garrigues O, Fessi H, Elaissari A. Nanocapsules prepared via nanoprecipitation and emulsification-diffusion methods: comparative study. *Eur J Pharm Biopharm.* 2012;80:235-9.
- Müller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. *Int J Pharm.* 2002;237:151-61.
- Munoz-Bonilla A, Herk AMV, Heuts JPA. Preparation of hairy particles and antifouling films using brush-type amphiphilic block copolymer surfactants in emulsion polymerization. *Macromolecules.* 2010;43:2721-31.
- Musyanovych A, Schmitz-Wienke J, Mailander V, Walther P, Land-fester K. Preparation of biodegradable polymer nanoparticles by miniemulsion technique and their cell interactions. *Macromol Biosci.* 2008;8:127-39.
- Mylonaki I, Strano F, Deglise S, Allémann E, Alonso F, Corpataux JM, Dubuis C, Haefliger JA, Jordan O, Saucy F, Delie F. Perivascular sustained release of atorvastatin from a hydrogel-microparticle delivery system decreases intimal hyperplasia. *J Control Release.* 2016;232:93-102.
- Nagaoka K, Matoba T, Mao Y, Nakano Y, Ikeda G, Egusa S, Tokutme M, Nagahama R, Nakano K, Sunagawa K, Egashira K. A new therapeutic modality for acute myocardial infarction: nanoparticle-mediated delivery of pitavastatin induces cardioprotection from ischemia-reperfusion injury via activation of PI3K/Akt pathway and anti-inflammation in a rat model *PloS One.* 2015;10:e0132451.
- Nehilla BJ, Bergkvist M, Popat KC, Desai TA. Purified and surfactant-free coenzyme Q10-loaded biodegradable nanoparticles. *Int J Pharm.* 2008;348:107-14.
- Nguyen CA, Allemann E, Schwach G, Doelker E, Gurny R. Synthesis of a novel fluorescent poly(d, l-lactide) end-capped with 1-pyrenebutanol used for the preparation of nanoparticles. *Eur J Pharm Sci.* 2003;20:217-22.
- Nicolas J, Charleux B, Guerret O, Magnet S. Nitroxide-mediated controlled free-radical emulsion polymerization using a difunctional water-soluble alkoxyamine initiator. Toward the control of particle size, particle size distribution, and the synthesis of triblock copolymers. *Macromolecules.* 2005;38:9963-73.
- Ohsfeldt RL, Gandhi SK, Fox KM, Bullano MF, Davidson M. Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. *J Med Econ.* 2010;13:500-7.

- Oörni K, Pentikäinen MO, Ala-Korpela M, Kovanen PT. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. *J Lipid Res.* 2000;41:1703-14.
- Park KH, Song HC, Na K, Bom HS, Lee KH, Kim S, Kang D, Lee DH. Ionic strength-sensitive pullulan acetate nanoparticles (PAN) for intra-tumoral administration of radioisotope: ionic strength-dependent aggregation behavior and ^{99m}Tc retention property. *Colloid Surf B.* 2007;59:16-23.
- Patel RR, Chaurasia S, Khan G, Chaubey P, Kumar N, Mishra B. Cromolyn sodium encapsulated PLGA nanoparticles: An attempt to improve intestinal permeation. *I J Biolog Macromol.* 2016;83:249-58.
- Patel RR, Chaurasia S, Khan G, Chaubey P, Kumar N, Mishra B. Highly water-soluble mast cell stabiliser-encapsulated solid lipid nanoparticles with enhanced oral bioavailability. *J Microencapsul.* 2016;33:209-20.
- Patel RR, Khan G, Chaurasia S, Kumar N, Mishra B. Rationally developed core-shell polymeric-lipid hybrid nanoparticles as a delivery vehicle for cromolyn sodium: implications of lipid envelop on *in vitro* and *in vivo* behaviour of nanoparticles upon oral administration. *RSC Adv.* 2015;5:76491-506.
- Patil YB, Toti US, Khdair A, Ma L, Panyam J. Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. *Biomaterials.* 2009;30:859-66.
- Peer D, Karp JM, Hong S, Farokhzad O, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nat. Nanotechnol.* 2007;2:751-760.
- Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. *Eur J Pharm Biopharm.* 2015;93:52-79.
- Prabhu P, Patravale V. Dissolution enhancement of atorvastatin calcium by co-grinding technique. *Drug Deliv Transl Res.* 2015.
- Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle technologies for oral drug delivery. *Clin Gastroenterol Hepatol.* 2014;12:1605-10.
- Prueitt RL, Cohen JM, Goodman JE. Evaluation of atherosclerosis as a potential mode of action for cardiovascular effects of particulate matter. *Regulatory Toxicol and Pharmacol.* 2015;73:S1-S15.
- Puig JE. Microemulsion polymerization (oil-in water). In: Salamone JC, editor. *Polymeric materials encyclopedia*, vol. 6. Boca Raton, FL: CRC Press; 1996. p. 4333-41.
- Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ. Protein encapsulation within poly(ethylene glycol)-coated nanospheres. II. Controlled release properties. *J Biomed Mater Res A.* 1999;47:388-95.

- Rangel-Yagui CO, Pessoa Jr A, Tavares LC. Micellar solubilization of drugs. *J Pharm Pharmaceut Sci.* 2005;8:147-63.
- Rao JP, Geckeler KE. Polymer nanoparticles: Preparation techniques and size-control parameters. *Progress Poly. Sci.* 2011;36:887-913.
- Rawat MK, Jain A, Singh S. *In vivo* and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. *J Pharm Sci.* 2011;100:2406-17.
- Reverchon E. Supercritical antisolvent precipitation of micro-and nanoparticles. *J Supercrit Fluids.* 1999;15:1-21.
- Rohilla R, Garg T, Bariwal J, Goyal AK, Rath G. Development, optimization and characterization of glycyrrhetic acid-chitosan nanoparticles of atorvastatin for liver targeting. *Drug Deliv.* 2015:e1-e8.
- Rotureau E, Raynaud J, Choquenot B, Marie E, Nouvel C, Six JL, Del-lacherie E, Durand A. Application of amphiphilic polysaccharides as stabilizers in direct and inverse free-radical miniemulsion polymerization. *Colloid Surf A.* 2008;331:84-90.
- Rowe RC, Sheshkey PJ, Quinn M. *Handbook of Pharmaceutical Excipients.* 6th Edn. Lonon: Pharmaceutical Press, 2009.
- Sadoqi M, Lau-Cam CA, Wu SH. Investigation of the micellar properties of the tocopheryl polyethylene glycol succinate surfactants TPGS 400 and TPGS 1000 by steady state fluorometry. *J Colloid Interface Sci.* 2009;333:585-9.
- Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicine. *Nat. Nanotechnol.* 2008;3:242-244.
- Schaftenaar F, Frodermann V, Kuiper J, Lutgens E. Atherosclerosis: the interplay between lipids and immune cells. *Curr Opin Lipidol.* 2016;27:209-15.
- Seyler I, Appel M, Devissaguet JP, Legrand P, Barratt G. Macrophage activation by a lipophilic derivative of muramyl dipeptide within nanocapsules: investigation of the mechanism of drug delivery. *J Nanopart Res.* 1999;1:91-7.
- Shah Y, Iqbal Z, Ahmad L, Khan A, Khan MI, Nazir S, Nasir F. Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2011;879:557-63.
- Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. *Eur J Pharm Sci.* 2009;37:223-30.
- Shariati A, Peters CJ. Recent developments in particle design using supercritical fluids. *Curr Opin Solid State Mater Sci.* 2003;7:371-83.
- Sharma K, Hallan SS, Lal B, Bhardwaj A, Mishra N. Development and characterization of floating spheroids of atorvastatin calcium loaded NLC

- for enhancement of oral bioavailability. *Artif Cells Nanomed Biotechnol.* 2015;1-9.
- Sharma PA, Maheshwari R, Tekade M, Tekade RK. Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases. *Curr Pharm Des.* 2015;21:4465-78.
- Shayanfar A, Ghavimi H, Hamishekar H, Jouyban A. Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties. *J Pharm Pharm Sci.* 2013;16:577-87.
- Shen H, Zhong M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. *J Pharm Pharmacol.* 2006;58:1183-91.
- Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. *Pharmacol Ther.* 2006;112:71-105.
- Siepmann J, Göpferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. *Adv Drug Deliv Rev.* 2001;48:229-47.
- Sigma Product Information, <http://www.sigmaaldrich.com/content/dam/sigmaaldrich/docs/Sigma/Instructions/detergent_selection_table.pdf>, 2013 (accessed on 26.02.2013), part of Sigma Aldrich Co. <<http://www.sigmaaldrich.com/>> (accessed 26.02.2013).
- Singh B, Kumar R, Ahuja N, Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects. *Crit Rev Ther Drug Carrier Syst.* 2005;22:27-105.
- Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, Cai Z, Li Y, Chen Q. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. *Eur J Pharm Biopharm.* 2008;69:445-53.
- Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. *J Control Release.* 2001;70:1-20.
- Sosa N, Zaragoza EA, Lopez RG, Peralta RD, Katime I, Becerra F, Mendizabal E, Puig JE. Unusual free radical polymerization of vinyl acetate in anionic microemulsion media. *Langmuir.* 2000;16:3612-9.
- Sripriyalakshmi S, Anjali CH, George PD, Rajith B, Ravindran A. BSA nanoparticle loaded atorvastatin calcium - a new facet for an old drug. *PLoS One.* 2014;9:e86317.
- Stella B, Arpicco S, Rocco F, Marsaud V, Renoir JM, Cattel L, Couvreur P. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. *Int J Pharm.* 2007;344:71-7.
- Storm G, Belliot SO, Daemenb T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. *Adv Drug Deliv Rev.* 1995;17: 31-48.

- Stormer H, Kleebe HJ, Ziegler G. Metastable SiCN glass matrices studied by energy-filtered electron diffraction pattern analysis. *J. Non-Cryst. Solids*. 2007;353: 2867-77.
- Stubbs C, Kanfer I. A stability indicating high-performance liquid chromatographic assay of erythromycin estolate in pharmaceutical dosage forms. *Int J Pharm*. 1990;63:113-19.
- Su-Jung Y, Chun H, Mi-Sun L, Kim N. Preparation of poly(N-vinylcarbazole) (PVK) nanoparticles by emulsion polymerization and PVK hollow particles. *Synth Met*. 2009;159:518-22.
- Sun G, Li Y, Ji Z. Atorvastatin attenuates inflammation and oxidative stress induced by ischemia/reperfusion in rat heart via the Nrf2 transcription factor. *Int J Clin Exp Med*. 2015;8:14837-45.
- Swarnakar NK, Jain AK, Singh RP, Godugu C, Das M, Jain S. Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles. *Biomaterials*. 2011;32:6860-74.
- Tabata Y, Ikada Y. Phagocytosis of polymer microspheres by macrophages. *Adv Polym Sci*. 1990;94:107-41.
- Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. *Pharmacol Ther*. 2006;109:137-61.
- Tan Y, Wang P, Xu K, Li W, An H, Li L, Liu C, Dong L. Designing starch-based nanospheres to make hydrogels with high mechanical strength. *Macromol Mater Eng*. 2009;294:855-9.
- Thompson MM, Reed SC, Cockerill GW. Therapeutic approaches to raising plasma HDL-cholesterol levels. *Nat Clin Pract Cardiovasc Med*. 2004;1:84-9.
- Tomkin GH, Owens D. LDL as a cause of atherosclerosis. *The Open Atheroscl & Thromb J*. 2012;5:13-21.
- Torini L, Argillier JF, Zydowicz N. Interfacial polycondensation encapsulation in miniemulsion. *Macromolecules*. 2005;38:3225-36.
- Ubrich N, Schmidt C, Bodmeier R, Hoffman M, Maincent P. Oral evaluation in rabbits of cyclosporine-loaded Eudragit RS or RL nanoparticles. *Int J Pharm*. 2005;288:169-175.
- United States Pharmacopoeia. United States Pharmacopoeial Convention: Rockville, MD, 2009.
- Uskoković V. Entering the era of nanoscience: time to be so small. *J Biomed Nanotechnol*. 2013;9:1441-70.
- Vaculikova E, Grunwaldova V, Kral V, Dohnal J, Jampilek J. Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation. *Molecules*. 2012;17:13221-34.
- Verma S, Lan Y, Gokhale R, Burgess DJ. Quality by design approach to understand the process of nanosuspension preparation. *Int J Pharm*. 2009;377:185-98.

- Vidal F, Colomé C, Martínez-González J, Badimon L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. *Eur J Biochem.* 1998;252:378-84.
- Vuddanda PR, Rajamanickam VM, Yaspal M, Singh S. Investigations on agglomeration and haemocompatibility of vitamin E TPGS surface modified berberine chloride nanoparticles. *Biomed Res Int.* 2014. (doi: 10.1155/2014/951942)
- Wang S, Wang X, Zhang Z. Preparation of polystyrene particles with narrow particle size distribution by Y-ray initiated miniemulsion polymerization stabilized by polymeric surfactant. *Eur Polym J.* 2007;43:178-84.
- Wang Y, Larsson M, Huang W, Chiou S, Nicholls SJ, Chao J, Liua D. The use of polymer-based nanoparticles and nanostructured materials in treatment and diagnosis of cardiovascular diseases: Recent advances and emerging designs. *Prog Polym Sci.* 2016;57:153-78.
- Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D. Stability of nanosuspensions in drug delivery. *J Control Release.* 2013;172:1126-41.
- Woodruff MA, Hutmacher DW. The return of a forgotten polymer—polycaprolactone in the 21st century. *Progress Poly Sci.* 2010;35:1217-56.
- Wu M, Dellacherie E, Durand A, Marie E. Poly(n-butyl cyanoacrylate) nanoparticles via miniemulsion polymerization (1): dextran-based surfactants. *Colloid Surf B Biointerfaces.* 2009;69:141-6.
- Xu CB, Stenman E, Edvinsson L. Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. *Biochem Pharmacol.* 2002;64:497-505.
- Xu F, Yuan Y, Shan X, Liu C, Tao X, Sheng Y, Zhou H. Long-circulation of hemoglobin-loaded polymeric nanoparticles as oxygen carriers with modulated surface charges. *Int J Pharm.* 2009;377:199-06.
- Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. *J Colloid Interface Sci.* 2010;351:19-29.
- Yamanaka YJ, Leong KW. Engineering strategies to enhance nanoparticle-mediated oral delivery. *J Biomater Sci Polym Ed.* 2008;19:1549-70.
- Yamashita S, Yamamoto KT, Ohama T, Toyama YN, Nishida M. Molecular mechanisms of HDL cholesterol elevation by statins and its effects on HDL functions. *J Atheroscler Thromb.* 2010;17:436–51.
- Ye Y, Nishi SP, Manickavasagam S, Lin Y, Huang MH, Perez-Polo JR, Uretsky BF, Birnbaum Y. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. *Prostaglandins Other Lipid Mediat.* 2007;84:43-53.
- Yeom DW, Son HY, Kim JH, Kim SR, Lee SG, Song SH, Chae BR, Choi YW. Development of a solidified self-microemulsifying drug delivery system (S-

- SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability. *Int J Pharm.* 2016;506:302-11.
- Yeom DW, Song YS, Kim SR, Lee SG, Kang MH, Lee S, Choi YW. Development and optimization of a self-microemulsifying drug delivery system for atorvastatin calcium by using D-optimal mixture design. *Int J Nanomedicine.* 2015;10:3865-77.
- Yildiz U, Landfester K. Miniemulsion polymerization of styrene in the presence of macromonomeric initiators. *Polymer.* 2008;49:4930-4.
- Yokoyama M. Block copolymers as drug carriers. *Crit Rev Ther Drug Carrier Syst.* 1992;9:213-48.
- Yordanov GG, Dushkin CD. Preparation of poly(butylcyanoacrylate) drug carriers by nanoprecipitation using a pre-synthesized polymer and different colloidal stabilizers. *Colloid Polym Sci.* 2010;288:1019-26.
- York P. Strategies for particle design using supercritical fluid technologies. *Pharm Sci Technol Today.* 1999;2:430-40.
- Yoshino M, Kuhlmann MK, Kotanko P, Greenwood RN, Pisoni RL, Port FK, Jager KJ, Homel P, Augustijn H, de Charro FT, Collart F, Erek E, Finne P, Garcia-Garcia G, Grönhagen-Riska C, Ioannidis GA, Ivis F, Leivestad T, Løkkegaard H, Lopot F, Jin DC, Kramar R, Nakao T, Nandakumar M, Ramirez S, van der Sande FM, Schön S, Simpson K, Walker RG, Zaluska W, Levin NW. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. *J Am Soc Nephrol.* 2006;17:3510-9.
- Young EJ, Hasanjani Roushan MR, Shafae S, Genta RM, Taylor SL. Liver histology of acute brucellosis caused by *Brucella melitensis*. *Hum Pathol.* 2014;45:2023-8.
- Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. *Pharm Res.* 2008;25:781-791.
- Yusuf S, Ôunpuu S, Anand S. The Global Epidemic of Atherosclerotic Cardiovascular Disease. *Med Principles Pract.* 2002;11:3-8.
- Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties. *J Biomed Mater Res A.* 1999;44:109-15.
- Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrude P, Vigneron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. *J Control Release.* 1998;50:31-40.
- Zetterlund PB, Kagawa Y, Okubo M. Controlled/living radical polymerization in dispersed systems. *Chem Rev.* 2008;108:3747-94.
- Zetterlund PB, Nakamura T, Okubo M. Mechanistic investigation of particle size effects in TEMPO-mediated radical polymerization of styrene in aqueous miniemulsion. *Macromolecules.* 2007;40:8663-72.

- Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF. Micronization of atorvastatin calcium by antisolvent precipitation process. *Int J Pharm.* 2009;374:106-13.
- Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. *Biomaterials.* 2012;33:4889-906.
- Zheng Y, Chen H, Zeng X, Liu Z, Xiao X, Zhu Y, Gu D, Mei L. Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy. *Nanoscale Res Lett.* 2013;8:161. (doi: 10.1186/1556-276X-8-161)
- Zili Z, Sfar S, Fessi H. Preparation and characterization of poly- ϵ -caprolactone nanoparticles containing griseofulvin. *Int J Pharm.* 2005;294:261-7.
- Zweers MLT, Engbers GHM, Grijpma DW, Feijen J. In vitro degradation of nanoparticles prepared from polymers based on dl-lactide, glycolide and poly(ethylene oxide). *J Control Release.* 2004;100:347-56.
- Zweers MLT, Engbers GHM, Grijpma DW, Feijen J. Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles. *J Control Release.* 2006;114:317-24.

